Covalon Technologies (CVE:COV) Hits New 1-Year High – Still a Buy?

Covalon Technologies Ltd. (CVE:COV)’s share price hit a new 52-week high on Tuesday . The company traded as high as C$3.64 and last traded at C$3.54, with a volume of 7231 shares. The stock had previously closed at C$3.60.

Covalon Technologies Stock Down 3.9%

The firm has a 50-day simple moving average of C$2.47 and a 200 day simple moving average of C$2.15. The company has a market capitalization of C$95.56 million, a PE ratio of 21.62 and a beta of 1.40. The company has a debt-to-equity ratio of 5.35, a current ratio of 8.56 and a quick ratio of 6.45.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.